Stocks Coverage on the Healthcare Sector for Biostar Pharma, GlobeImmune, Neuralstem, and GW Pharma

July 18, 2016   |   9:15 am

Contributor: Tom Johnson, Active Wall Street


Active Wall St. announces the list of stocks for today’s coverage. Pre-market the Active Wall St. team provides the latest corporate, fundamental and technical events impacting selected stocks on the Healthcare sector. Companies recently under review include Biostar Pharma, GlobeImmune, Neuralstem, and GW Pharma. Register with us now for your free membership and more at:

Today, AWS is promoting its equity coverage. Get all of our research notes free by signing up to

Active Wall St. takes a brief technical look at how each of the companies mentioned above have fared over the last few trading sessions. On Friday, July 15, 2016, the NASDAQ Composite ended the trading session at 5,029.59, down 0.09%; the Dow Jones Industrial Average edged 0.05% higher, to finish at 18,516.55; and the S&P 500 closed at 2,161.74, down 0.09%. The gains were broad based as five out of nine sectors ended the session in positive.

Biostar Pharmaceuticals Inc. develops, manufactures, and markets over-the-counter (OTC) and prescription pharmaceutical products for various diseases and conditions in the People’s Republic of China. The stock finished Friday’s session 0.25% higher at $3.99 with a total volume of 86,600 shares traded.


The Company’s shares have rallied 182.98% in the past three months. The stock is trading above its 50-day and 200-day moving averages by 38.18% and 31.50%, respectively. Biostar Pharmaceuticals’ stock has a Relative Strength Index (RSI) of 50.63. See our complete notes on BSPM at:

On Friday, shares in Louisville, Colorado headquartered biopharmaceutical company, GlobeImmune Inc., ended the session 1.94% lower at $0.91 with a total volume of 103,317 shares traded.


The stock is trading 40.02% below its 50-day moving average. Moreover, shares of GlobeImmune have an RSI of 36.98. The Company has strategic collaborations with Gilead Sciences Inc. and Celgene Corporation. The complimentary notes on GBIM can be accessed at:

On Friday, shares in Germantown, Maryland headquartered clinical stage biopharmaceutical company, Neuralstem Inc., which focuses on the research, development, and commercialization of central nervous system therapies based on its proprietary human neuronal stem cells and stem-cell derived small molecule compounds, ended the day 1.85% lower at $0.26 with a total volume of 334,916 shares traded.


The stock is trading below its 50-day moving average by 17.94%. Furthermore, shares of Neuralstem have an RSI of 34.91. Register for free on Active Wall St. and access the latest notes on CUR at:

GW Pharmaceuticals PLC, a biopharmaceutical company, together with its subsidiaries, engages in discovering, developing, and commercializing cannabinoid prescription medicines. The stock edged 0.67% lower to close the day at $90.39 with a total volume of 521,667 shares traded.


The Company’s shares have advanced 4.84% in the last one month and 9.84% in the past three months. The stock is trading 3.48% and 20.75% above its 50-day and 200-day moving averages, respectively. Additionally, GW Pharmaceuticals’ stock has an RSI of 50.61. Get free access to your notes on GWPH at:

Active Wall Street:

Active Wall Street (AWS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. AWS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

AWS has not been compensated; directly or indirectly; for producing or publishing this document.


The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by AWS. AWS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.


AWS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. AWS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, AWS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither AWS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit


For any questions, inquiries, or comments reach out to us directly. If you’re a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Phone number: 1-858-257-3144
Office Address: 3rd floor, 207 Regent Street, London, W1B 3HH, United Kingdom

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.